Challenges of developing R5 inhibitors in antiretroviral naive HIV-infected patients

被引：15

作者：

Deeks, SG ^{[1
]}

机构：

[1] Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA 94110 USA

来源：

LANCET | 2006年 / 367卷 / 9512期

关键词：

D O I：

10.1016/S0140-6736(06)68280-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：711 / 713

页数：3

共 13 条

[1]

AJEUBOR MN, 2005, J IMMUNOL, V174, P8207

[2] Treatment of anti retroviral-drug-resistant HIV-1 infection [J].

Deeks, SG .

LANCET, 2003, 362 (9400) :2002-2011

[3] Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 [J].

Fätkenheuer, G ;

Pozniak, AL ;

Johnson, MA ;

Plettenberg, A ;

Staszewski, S ;

Hoepelman, AIM ;

Saag, MS ;

Goebel, FD ;

Rockstroh, JK ;

Dezube, BJ ;

Jenkins, TM ;

Medhurst, C ;

Sullivan, JF ;

Ridgway, C ;

Abel, S ;

James, IT ;

Youle, M ;

van der Ryst, E .

NATURE MEDICINE, 2005, 11 (11) :1170-1172

[4] Efficacy and safety of tenofovir DF vs stavuldine in combination therapy in antiretroviral-naive patients - A 3-year randomized trial [J].

Gallant, JE ;

Staszewski, S ;

Pozniak, AL ;

DeJesus, E ;

Suleiman, JMAH ;

Miller, MD ;

Coakley, DF ;

Lu, B ;

Toole, JJ ;

Cheng, AK .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (02) :191-201

[5]

GREAVES W, 2006, 13 C RETR OPP INF

[6] Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection [J].

Gulick, RM ;

Ribaudo, HJ ;

Shikuma, CM ;

Lustgarten, S ;

Squires, KE ;

Meyer, WA ;

Acosta, EP ;

Schackman, BR ;

Pilcher, CD ;

Murphy, RL ;

Maher, WE ;

Witt, MD ;

Reichman, RC ;

Snyder, S ;

Klingman, KL ;

Kuritzkes, DR .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (18) :1850-1861

[7] PROGNOSTIC VALUE OF HIV-1 SYNCYTIUM-INDUCING PHENOTYPE FOR RATE OF CD4+ CELL DEPLETION AND PROGRESSION TO AIDS [J].

KOOT, M ;

KEET, IPM ;

VOS, AHV ;

DEGOEDE, REY ;

ROOS, MTL ;

COUTINHO, RA ;

MIEDEMA, F ;

SCHELLEKENS, PTA ;

TERSMETTE, M .

ANNALS OF INTERNAL MEDICINE, 1993, 118 (09) :681-688

[8] Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults [J].

Lalezari, J ;

Thompson, M ;

Kumar, P ;

Piliero, P ;

Davey, R ;

Patterson, K ;

Shachoy-Clark, A ;

Adkison, K ;

Demarest, J ;

Lou, Y ;

Berrey, M ;

Piscitelli, S .

AIDS, 2005, 19 (14) :1443-1448

[9] Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: Results from the EuroSIDA Study Group [J].

Mocroft, A ;

Ledergerber, B ;

Viard, JP ;

Staszewski, S ;

Murphy, M ;

Chiesi, A ;

Horban, A ;

Hansen, ABE ;

Phillips, AN ;

Lundgren, JD .

JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (11) :1947-1956

[10] The CCR5 and CXCR4 coreceptors - Central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection [J].

Moore, JP ;

Kitchen, SG ;

Pugach, P ;

Zack, JA .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 2004, 20 (01) :111-126

← 1 2 →